Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Verronese E ^a   Delgado, A ^a   Valladeau Guilemond, J ^b,c,d   Garin, G ^e   Guillemaut, S ^e   Tredan, O ^e   Ray Coquard, I ^e   Bachelot, T ^b,c,d,e   N'Kodia, A ^a   Bardin Dit Courageot, C ^a   Rigal, C ^a   Perol D ^e   Caux, C ^a,b,c,d   Menetrier Caux C ^a,b,c,d  

^a University of Lyon EA 7426 Pathophysiology of Injury Induced Immunosuppression PI3   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

Breast cancer; immune system; monitoring; multi parametric flow cytometry; whole blood assay

Indexed keywords

ALPHA2 INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MONOCYTE; NATURAL KILLER CELL; T LYMPHOCYTE ACTIVATION;

EID: 84961589517     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1100791     Document Type: Article

References (63)

1. G.Alexe, G.S.Dalgin, D.Scanfeld, P.Tamayo, J.P.Mesirov, C.DeLisi, L.Harris, N.Barnard, M.Martel, A.J.Levine et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67:10669-76; PMID:18006808; http://dx.doi.org/10.1158/0008-5472.CAN-07-0539
2. M.L.Ascierto, M.O.Idowu, Y.Zhao, H.Khalak, K.K.Payne, X.Y.Wang, C.I.Dumur, D.Bedognetti, S.Tomei, P.A.Ascierto et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 2013; 11:145; PMID:23758773; http://dx.doi.org/10.1186/1479-5876-11-145
3. A.E.Teschendorff, A.Miremadi, S.E.Pinder, I.O.Ellis, C.Caldas. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8:R157; PMID:17683518; http://dx.doi.org/10.1186/gb-2007-8-8-r157
4. S.M.Mahmoud, E.C.Paish, D.G.Powe, R.D.Macmillan, M.J.Grainge, A.H.Lee, I.O.Ellis, A.R.Green. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
5. I.Le Mercier, D.Poujol, A.Sanlaville, V.Sisirak, M.Gobert, I.Durand, B.Dubois, I.Treilleux, J.Marvel, J.Vlach et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; 73:4629-40; PMID:23722543; http://dx.doi.org/10.1158/0008-5472.CAN-12-3058
6. V.Sisirak, J.Faget, M.Gobert, N.Goutagny, N.Vey, I.Treilleux, S.Renaudineau, G.Poyet, S.I.Labidi-Galy, S.Goddard-Leon et al. Impaired IFN-alpha Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468
7. V.Sisirak, N.Vey, N.Goutagny, S.Renaudineau, M.Malfroy, S.Thys, I.Treilleux, S.I.Labidi-Galy, T.Bachelot, C.Dezutter-Dambuyant et al. Breast cancer-derived transforming growth factor-beta and tumor necrosis factor-alpha compromise interferon-alpha production by tumor-associated plasmacytoid dendritic cells. Int J Cancer 2013; 133:771-8; PMID:23389942; http://dx.doi.org/10.1002/ijc.28072
8. J.Faget, C.Biota, T.Bachelot, M.Gobert, I.Treilleux, N.Goutagny, I.Durand, S.Léon-Goddard, J.Y.Blay, C.Caux et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res 2011; 71:6143-52; PMID:21852386; http://dx.doi.org/10.1158/0008-5472.CAN-11-0573
9. J.Faget, N.Bendriss-Vermare, M.Gobert, I.Durand, D.Olive, C.Biota, T.Bachelot, I.Treilleux, S.Goddard-Leon, E.Lavergne et al. ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells. Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi.org/10.1158/0008-5472.CAN-12-2409
10. M.Gobert, I.Treilleux, N.Bendriss-Vermare, T.Bachelot, S.Goddard-Leon, V.Arfi, C.Biota, A.C.Doffin, I.Durand, D.Olive et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-9; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360
11. S.Ferrari, F.Malugani, B.Rovati, C.Porta, A.Riccardi, M.Danova. Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. Oncol Rep 2005; 14:113-20; PMID:15944777
12. M.Manuel, O.Tredan, T.Bachelot, G.Clapisson, A.Courtier, G.Parmentier, T.Rabeony, A.Grives, S.Perez, J.F.Mouret et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology 2012; 1:432-40; PMID:22754761; http://dx.doi.org/10.4161/onci.19545
13. O.Tredan, M.Manuel, G.Clapisson, T.Bachelot, S.Chabaud, C.Bardin-Dit-Courageot, C.Rigal, C.Biota, A.Bajard, N.Pasqual et al. Patients with metastatic breast cancer leading to CD4(+) T cell lymphopaenia have poor outcome. Eur J Cancer 2013; 49:1673-82; PMID:23265706; http://dx.doi.org/10.1016/j.ejca.2012.11.028
14. J.F.Head, R.L.Elliott, J.L.McCoy. Evaluation of lymphocyte immunity in breast cancer patients. Breast Cancer Res Treat 1993; 26:77-88; PMID:8400326; http://dx.doi.org/10.1007/BF00682702
15. M.J.Campbell, J.Scott, H.T.Maecker, J.W.Park, L.J.Esserman. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat 2005; 91:163-71; PMID:15868444; http://dx.doi.org/10.1007/s10549-004-7048-0
16. S.Goto, M.Sato, R.Kaneko, M.Itoh, S.Sato, S.Takeuchi. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 1999; 48:435-42; PMID:10550548; http://dx.doi.org/10.1007/s002620050620
17. C.Verma, J.M.Eremin, A.Robins, A.J.Bennett, G.P.Cowley, M.A.El-Sheemy, J.A.Jibril, O.Eremin. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 2013; 11:16; PMID:23320561; http://dx.doi.org/10.1186/1479-5876-11-16
18. C.Horlock, B.Stott, P.J.Dyson, M.Morishita, R.C.Coombes, P.Savage, J.Stebbing. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 2009; 100:1061-7; PMID:19277040; http://dx.doi.org/10.1038/sj.bjc.6604963
19. D.Piccioli, S.Tavarini, E.Borgogni, V.Steri, S.Nuti, C.Sammicheli, M.Bardelli, D.Montagna, F.Locatelli, A.Wack. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007; 109:5371-9; PMID:17332250; http://dx.doi.org/10.1182/blood-2006-08-038422
20. S.Balan, V.Ollion, N.Colletti, R.Chelbi, F.Montanana-Sanchis, H.Liu, T.P.Vu Manh, C.Sanchez, J.Savoret, I.Perrot et al. Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. J Immunol 2014; 193:1622-35; PMID:25009205; http://dx.doi.org/10.4049/jimmunol.1401243
21. H.Lauterbach, B.Bathke, S.Gilles, C.Traidl-Hoffmann, C.A.Luber, G.Fejer, M.A.Freudenberg, G.M.Davey, D.Vremec, A.Kallies et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 2010; 207:2703-17; PMID:20975040; http://dx.doi.org/10.1084/jem.20092720
22. A.Bachem, S.Guttler, E.Hartung, F.Ebstein, M.Schaefer, A.Tannert, A.Salama, K.Movassaghi, C.Opitz, H.W.Mages et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
23. F.Deauvieau, V.Ollion, A.C.Doffin, C.Achard, J.F.Fonteneau, E.Verronese, I.Durand, R.Ghittoni, J.Marvel, C.Dezutter-Dambuyant et al. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer 2015; 136:1085-94; PMID:25046660; http://dx.doi.org/10.1002/ijc.29087
24. S.L.Jongbloed, A.J.Kassianos, K.J.McDonald, G.J.Clark, X.Ju, C.E.Angel, C.J.Chen, P.R.Dunbar, R.B.Wadley, V.Jeet et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:20479116; http://dx.doi.org/10.1084/jem.20092140
25. L.F.Poulin, M.Salio, E.Griessinger, F.Anjos-Afonso, L.Craciun, J.L.Chen, A.M.Keller, O.Joffre, S.Zelenay, E.Nye et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1261-71; PMID:20479117; http://dx.doi.org/10.1084/jem.20092618
26. B.Reizis, A.Bunin, H.S.Ghosh, K.L.Lewis, V.Sisirak. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol 2011; 29:163-83; PMID:21219184; http://dx.doi.org/10.1146/annurev-immunol-031210-101345
27. B.S.Della, M.Gennaro, M.Vaccari, C.Ferraris, S.Nicola, A.Riva, M.Clerici, M.Greco, M.L.Villa et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003; 89:1463-72; PMID:14562018; http://dx.doi.org/10.1038/sj.bjc.6601243
28. I.Caras, A.Grigorescu, C.Stavaru, D.L.Radu, I.Mogos, G.Szegli, A.Salageanu. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004; 53:1146-52; PMID:15185014; http://dx.doi.org/10.1007/s00262-004-0556-2
29. S.R.Woo, L.Corrales, T.F.Gajewski. Innate immune recognition of cancer. Annu Rev Immunol 2015; 33:445-74; PMID:25622193; http://dx.doi.org/10.1146/annurev-immunol-032414-112043
30. F.Gerosa, B.Baldani-Guerra, C.Nisii, V.Marchesini, G.Carra, G.Trinchieri. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195:327-33; PMID:11828007; http://dx.doi.org/10.1084/jem.20010938
31. L.Moretta, G.Ferlazzo, C.Bottino, M.Vitale, D.Pende, M.C.Mingari, A.Moretta. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006; 214:219-28; PMID:17100887; http://dx.doi.org/10.1111/j.1600-065X.2006.00450.x
32. E.Mamessier, A.Sylvain, M.L.Thibult, G.Houvenaeghel, J.Jacquemier, R.Castellano, A.Gonçalves, P.André, F.Romagné, G.Thibault et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816
33. M.Chittezhath, M.K.Dhillon, J.Y.Lim, D.Laoui, I.N.Shalova, Y.L.Teo, J.Chen, R.Kamaraj, L.Raman, J.Lum et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 2014; 41:815-29; PMID:25453823; http://dx.doi.org/10.1016/j.immuni.2014.09.014
34. R.N.Ramos, L.S.Chin, A.P.Dos Santos, P.C.Bergami-Santos, F.Laginha, J.A.Barbuto. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J Leukoc Biol 2012; 92:673-82; PMID:22636320; http://dx.doi.org/10.1189/jlb.0112048
35. B.S.Della, S.Giannelli, A.Taddeo, P.Presicce, M.L.Villa. Application of six-color flow cytometry for the assessment of dendritic cell responses in whole blood assays. J Immunol Methods 2008; 339:153-64; PMID:18835394; http://dx.doi.org/10.1016/j.jim.2008.09.009
36. D.Duffy, V.Rouilly, V.Libri, M.Hasan, B.Beitz, M.David, A.Urrutia, A.Bisiaux, S.T.Labrie, A.Dubois et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 2014; 40:436-50; PMID:24656047; http://dx.doi.org/10.1016/j.immuni.2014.03.002
37. C.Hemont, A.Neel, M.Heslan, C.Braudeau, R.Josien. Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J Leukoc Biol 2013; 93:599-609; PMID:23341538; http://dx.doi.org/10.1189/jlb.0912452
38. J.A.Ida, N.Shrestha, S.Desai, S.Pahwa, W.A.Hanekom, P.A.Haslett. A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J Immunol Methods 2006; 310:86-99; PMID:16455104; http://dx.doi.org/10.1016/j.jim.2005.12.008
39. S.C.Mueller, R.Marz, M.Schmolz, B.Drewelow. Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application. BMC Med Res Methodol 2012; 12:112; PMID:22853196; http://dx.doi.org/10.1186/1471-2288-12-112
40. M.S.Shey, E.J.Hughes, K.M.de, C.Barnard, L.Stone, T.R.Kollmann, W.A.Hanekom, T.J.Scriba. Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. J Immunol Methods 2012; 376:79-88; PMID:22155193; http://dx.doi.org/10.1016/j.jim.2011.11.011
41. K.Jansen, D.Blimkie, J.Furlong, A.Hajjar, A.Rein-Weston, J.Crabtree, B.Reikie, C.Wilson, T.Kollmann. Polychromatic flow cytometric high-throughput assay to analyze the innate immune response to Toll-like receptor stimulation. J Immunol Methods 2008; 336:183-92; PMID:18565537; http://dx.doi.org/10.1016/j.jim.2008.04.013
42. V.Appay, R.A.van Lier, F.Sallusto, M.Roederer. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73:975-83; PMID:18785267; http://dx.doi.org/10.1002/cyto.a.20643
43. L.Ziegler-Heitbrock, P.Ancuta, S.Crowe, M.Dalod, V.Grau, D.N.Hart, P.J.Leenen, Y.J.Liu, G.MacPherson, G.J.Randolph et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116:e74-e80; PMID:20628149; http://dx.doi.org/10.1182/blood-2010-02-258558
44. I.Perrot, F.Deauvieau, C.Massacrier, N.Hughes, P.Garrone, I.Durand, O.Demaria, N.Viaud, L.Gauthier, M.Blery et al. TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol 2010; 185:2080-8; PMID:20639488; http://dx.doi.org/10.4049/jimmunol.1000532
45. K.S.Gorski, E.L.Waller, J.Bjornton-Severson, J.A.Hanten, C.L.Riter, W.C.Kieper, K.B.Gorden, J.S.Miller, J.P.Vasilakos, M.A.Tomai et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006; 18:1115-26; PMID:16728430; http://dx.doi.org/10.1093/intimm/dxl046
46. J.D.Marshall, D.S.Heeke, C.Abbate, P.Yee, N.G.Van. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology 2006; 117:38-46; PMID:16423039; http://dx.doi.org/10.1111/j.1365-2567.2005.02261.x
47. J.Zhu, X.Huang, Y.Yang. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol Ther 2008; 16:1300-7; PMID:18443600; http://dx.doi.org/10.1038/mt.2008.88
48. A.Gaafar, M.D.Aljurf, A.Al-Sulaiman, A.Iqniebi, P.S.Manogaran, G.E.Mohamed, A.Al-Sayed, H.Alzahrani, F.Alsharif, F.Mohareb et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol 2009; 37:838-48; PMID:19446661; http://dx.doi.org/10.1016/j.exphem.2009.04.003
49. F.Gerosa, A.Gobbi, P.Zorzi, S.Burg, F.Briere, G.Carra, G.Trinchieri. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005; 174:727-34; PMID:15634892; http://dx.doi.org/10.4049/jimmunol.174.2.727
50. M.Haniffa, A.Shin, V.Bigley, N.McGovern, P.Teo, P.See, P.S.Wasan, X.N.Wang, F.Malinarich, B.Malleret et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37:60-73; PMID:22795876; http://dx.doi.org/10.1016/j.immuni.2012.04.012
51. N.L.Bernasconi, N.Onai, A.Lanzavecchia. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101:4500-4; PMID:12560217; http://dx.doi.org/10.1182/blood-2002-11-3569
52. A.Krug, A.Towarowski, S.Britsch, S.Rothenfusser, V.Hornung, R.Bals, T.Giese, H.Engelmann, S.Endres, A.M.Krieg et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31:3026-37; PMID:11592079; http://dx.doi.org/10.1002/1521-4141(2001010)31:10%3c3026::AID-IMMU3026%3e3.0.CO;2-H
53. D.Yen, J.Cheung, H.Scheerens, F.Poulet, T.McClanahan, B.McKenzie, M.A.Kleinschek, A.Owyang, J.Mattson, W.Blumenschein et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-6; PMID:16670770; http://dx.doi.org/10.1172/JCI21404
54. H.Yasukawa, A.Sasaki, A.Yoshimura. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000; 18:143-64; PMID:10837055; http://dx.doi.org/10.1146/annurev.immunol.18.1.143
55. M.Severa, M.E.Remoli, E.Giacomini, J.Ragimbeau, R.Lande, G.Uze, S.Pellegrini, E.M.Coccia. Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol 2006; 79:1286-94; PMID:16624932; http://dx.doi.org/10.1189/jlb.1205742
56. J.S.Lopez-Gonzalez, F.Avila-Moreno, H.Prado-Garcia, D.Aguilar-Cazares, J.J.Mandoki, M.Meneses-Flores. Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-alpha. Clin Immunol 2007; 122:323-9; PMID:17175197; http://dx.doi.org/10.1016/j.clim.2006.11.003
57. Y.Lou, C.Liu, G.J.Kim, Y.J.Liu, P.Hwu, G.Wang. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007; 178:1534-41; PMID:17237402; http://dx.doi.org/10.4049/jimmunol.178.3.1534
58. R.Botella-Estrada, M.Escudero, J.E.O'Connor, E.Nagore, B.Fenollosa, O.Sanmartin, C.Requena, C.Guillén. Cytokine production by peripheral lymphocytes in melanoma. Eur Cytokine Netw 2005; 16:47-55; PMID:15809206
59. I.Chatzidakis, C.Mamalaki. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun 2010; 11:105-18; PMID:20173390; http://dx.doi.org/10.1159/000289200
60. M.Shi, Z.Ye, K.S.Umeshappa, T.Moyana, J.Xiang. Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase. Biochem Biophys Res Commun 2007; 360:702-7; PMID:17618911; http://dx.doi.org/10.1016/j.bbrc.2007.06.126
61. H.Nakano, T.Kishida, H.Asada, M.Shin-Ya, T.Shinomiya, J.Imanishi, T.Shimada, S.Nakai, M.Takeuchi, Y.Hisa et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 2006; 8:90-9; PMID:16097036; http://dx.doi.org/10.1002/jgm.817
62. A.P.Sutherland, N.Joller, M.Michaud, S.M.Liu, V.K.Kuchroo, M.J.Grusby. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J Immunol 2013; 190:3977-84; PMID:23479229; http://dx.doi.org/10.4049/jimmunol.1201730
63. J.M.Roda, R.Parihar, A.Lehman, A.Mani, S.Tridandapani, W.E.Carson, III. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006; 177:120-9; PMID:16785506; http://dx.doi.org/10.4049/jimmunol.177.1.120